Vitamin K Antagonists: Examples and Clinical Context
Warfarin is the most commonly used vitamin K antagonist (VKA), with other examples including acenocoumarol and phenprocoumon 1, 2.
Specific VKA Medications
The three main vitamin K antagonists used clinically are:
- Warfarin - The most widely prescribed VKA globally, particularly in North America and many other regions 1, 2
- Acenocoumarol - Commonly used in several European countries 3, 2
- Phenprocoumon - Predominantly used in some European countries, particularly Germany and the Netherlands 2
All three drugs are administered as racemic mixtures (containing both enantiomeric forms) and work by inhibiting vitamin K epoxide reductase, thereby preventing the activation of vitamin K-dependent clotting factors 4, 2.
Key Clinical Characteristics
VKAs require INR monitoring with a target range of 2.0-3.0 for atrial fibrillation patients 1. The time in therapeutic range (TTR) should be maintained above 70% to ensure both safety and effectiveness 1.
Important Pharmacokinetic Differences
The three VKAs differ substantially in their metabolism 2:
- Warfarin: Primarily metabolized by CYP2C9, with almost complete elimination through metabolism
- Acenocoumarol: Also mainly metabolized by CYP2C9, similar to warfarin
- Phenprocoumon: Has the longest half-life and involves both CYP2C9 and CYP3A4 metabolism, plus significant biliary and urinary excretion of unchanged drug
Phenprocoumon may be preferable for patients who are CYP2C9 poor metabolizers due to its less pronounced dependence on this enzyme 2.
Current Clinical Role
VKAs remain the only anticoagulation option for patients with mechanical heart valves or moderate-to-severe mitral stenosis 1. For all other indications, direct oral anticoagulants (DOACs) are now preferred due to their superior safety profile, particularly regarding intracranial hemorrhage risk (50% reduction compared to warfarin) 1.
However, VKAs may be continued in clinically stable patients over age 75 with good TTR control and polypharmacy, as switching to DOACs in this specific population has shown increased bleeding risk 1.